Singapore, July 29 -- GSK plc has entered into agreements with China-based Hengrui Pharma to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031.
The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in class profiles.The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau and Taiwan) for a potential best-in-class, PDE3/4 inhibitor (HRS-9821) in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy. The addition of HR...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.